Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) have earned a consensus recommendation of “Hold” from the ten brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $67.75.
Several equities analysts have recently commented on the stock. BidaskClub raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. ValuEngine downgraded shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Zacks Investment Research raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. BMO Capital Markets raised shares of Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, October 16th. Finally, Royal Bank of Canada boosted their target price on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a report on Monday, November 6th.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas bought a new stake in Five Prime Therapeutics in the fourth quarter worth $221,000. Alps Advisors Inc. increased its position in Five Prime Therapeutics by 13.2% in the fourth quarter. Alps Advisors Inc. now owns 32,058 shares of the biotechnology company’s stock worth $703,000 after purchasing an additional 3,728 shares during the last quarter. Victory Capital Management Inc. increased its position in Five Prime Therapeutics by 73.5% in the fourth quarter. Victory Capital Management Inc. now owns 924,190 shares of the biotechnology company’s stock worth $20,258,000 after purchasing an additional 391,550 shares during the last quarter. Dupont Capital Management Corp increased its position in Five Prime Therapeutics by 201.8% in the fourth quarter. Dupont Capital Management Corp now owns 25,152 shares of the biotechnology company’s stock worth $551,000 after purchasing an additional 16,818 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in Five Prime Therapeutics in the fourth quarter worth $386,000. Institutional investors own 71.23% of the company’s stock.
Five Prime Therapeutics (NASDAQ FPRX) traded up $0.29 during mid-day trading on Friday, hitting $19.53. 334,247 shares of the stock traded hands, compared to its average volume of 547,137. Five Prime Therapeutics has a 1 year low of $17.83 and a 1 year high of $49.30. The stock has a market capitalization of $567.61, a P/E ratio of -3.87 and a beta of 3.56.
Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.19). Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The company had revenue of $8.33 million during the quarter, compared to analysts’ expectations of $16.16 million. During the same period last year, the firm posted ($0.72) EPS. Five Prime Therapeutics’s quarterly revenue was up 24.7% compared to the same quarter last year. analysts anticipate that Five Prime Therapeutics will post -5.56 earnings per share for the current fiscal year.
WARNING: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/14/analysts-set-five-prime-therapeutics-inc-fprx-target-price-at-67-75.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.